Adam Bonislawski

The device, commercially developed by startup Genio Technologies, could help physicians identify bacteria during surgery, accelerating tailored patient care.

COVID-19 drove an investment boom that pushed diagnostics innovation, but newer technologies could be in a precarious position as public funding and test sales slow.

While the bill includes an arbitration process that labs can use to fight cuts, some feel it is a cumbersome process, and it is already facing delays.

Changing business models and new legislative initiatives are driving point-of-care testing in pharmacies in the wake of the COVID-19 pandemic.

Even as layoffs hit labs due to declining demand for COVID-19 testing, a wave of departing workers and a depleted trainee pipeline make personnel hard to come by.

A panel discussion at the Next Generation Dx Summit this week provided perspectives on the bill from a variety of industry stakeholders.

The agency is drawing criticism for a proposed CLIA update that would recognize nursing degrees as sufficient education for performing high-complexity testing.

An amendment proposed by Sen. Tommy Tuberville would exempt academic medical centers from the law but appears to have little momentum.

The firm, which reported a 7 percent drop in Q2 revenues, is laying off roughly 130 workers as it focuses on improving assay quality and scaling its manufacturing.

Total revenues for the period were $179.3 million, down from $189.4 million, beating the consensus Wall Street estimate of $171.0 million.